drugset / Trial / NCT02839954
CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor
Phase 1/2
Unknown
10 enrolled
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Hefei Binhu Hospital · collabThe First People's Hospital of Hefei · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with MUC1 positive relapsed or refractory solid tumor.
Timeline
- Start
- 2016-07
- Primary completion
- 2017-07
- Completion
- 2018-07
Publications
- Lin J, Xu W, Xia L, Zhang C, Ge L, Gao J, Bao J, Xu Y, Sun X, Li H, Wang Y. A phase I trial of combination CAR-NK92MI immunotherapy by dual targeting MUC-1 and PD-L1 for patients with relapsed or refractory solid tumors: focus on non-small cell lung cancer. BMC Pulm Med. 2025 Oct 21;25(1):482. doi: 10.1186/s12890-025-03944-y.
- Del Zotto G, Marcenaro E, Vacca P, Sivori S, Pende D, Della Chiesa M, Moretta F, Ingegnere T, Mingari MC, Moretta A, Moretta L. Markers and function of human NK cells in normal and pathological conditions. Cytometry B Clin Cytom. 2017 Mar;92(2):100-114. doi: 10.1002/cyto.b.21508. Epub 2017 Feb 12.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-MUC1 CAR-pNK cells | Cell therapy | 1e+08 cells | — |
| Subject | anti-MUC1 CAR-pNK cells | Cell therapy | 2e+09 cells | — |